4 ms·

>> However, the cancer-killing pill Malkas has been developing over the past two decades, AOH1996, targets a cancerous variant of PCNA, a protein that in its mu

>> However, the cancer-killing pill Malkas has been developing over the past two decades, AOH1996, targets a cancerous variant of PCNA, a protein that in its mutated form is critical in DNA replication and repair of all expanding tumors But it's still a single pathway. Cancer has abilities to circumvent most pathways, after a time. Targeting multiple pathways will be the answer, but FDA is so slow at allowing multiple-target clinical trials. Keytruda thus far, has been the best to believe in combining with many other products, and get clinical trials going. Sure, they have to partner with competitors, but this (multi-pathways) is the true path to stopping cancer.

petra 3y ago
Why isn't it enough to combine a few approved drugs to target multiple pathways ?
D-Coder 3y ago
According to the article, this pathway is the same for all "expanding tumors": "PCNA is like a major airline terminal hub containing multiple plane gates. Data suggests PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells. Our cancer-killing pill is like a snowstorm that closes a key airline hub, shutting down all flights in and out only in planes carrying cancer cells..." This may be one pathway that cancers can't circumvent.
- adamredwoods 3y ago
  Consider taxol resistance. Taxols prevent microtubule formation, but yet, somehow, cells find a way to overcome this. They have only tested this in mice. >> We tested the anticancer activity of AOH1996 in mice bearing xenograft tumors derived from either neuroblastoma, breast cancer, or small cell lung cancer cells Cell function: https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(23)00221-0 https://www.cell.com/cell-chemical-biology/fulltext/S2451-94... Trials: https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2021-14102&r=1 https://www.cancer.gov/about-cancer/treatment/clinical-trial... I really hope this new chemo is powerful and adds to the list of agents we have to help stop metastatic cancer.

petra 3y ago

Why isn't it enough to combine a few approved drugs to target multiple pathways ?

D-Coder 3y ago

According to the article, this pathway is the same for all "expanding tumors": "PCNA is like a major airline terminal hub containing multiple plane gates. Data suggests PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells. Our cancer-killing pill is like a snowstorm that closes a key airline hub, shutting down all flights in and out only in planes carrying cancer cells..." This may be one pathway that cancers can't circumvent.

adamredwoods 3y ago
Consider taxol resistance. Taxols prevent microtubule formation, but yet, somehow, cells find a way to overcome this. They have only tested this in mice. >> We tested the anticancer activity of AOH1996 in mice bearing xenograft tumors derived from either neuroblastoma, breast cancer, or small cell lung cancer cells Cell function: https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(23)00221-0 https://www.cell.com/cell-chemical-biology/fulltext/S2451-94... Trials: https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2021-14102&r=1 https://www.cancer.gov/about-cancer/treatment/clinical-trial... I really hope this new chemo is powerful and adds to the list of agents we have to help stop metastatic cancer.